Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cetuximab in combination with Gemcitabine for treatment of advanced pancreatic cancer

A combination of Cetuximab and Gemcitabine proves promising as a treatment for advanced pancreatic cancer reports the Journal of Clinical Gastroenterology.

News image

fiogf49gjkf04

Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Researchers in the USA have now used it in combination with gemcitabine, an established anti-cancer drug, to treat patients with epidermal growth receptor-expressing advanced pancreatic cancer.

In a multicenter phase II clinical trial, Henry Q. Xiong and colleagues have determined the response rate, time to disease progression, survival duration and rate and toxicity, with the combination of cetuximab and gemcitabine in patients with EGFR-expressing advanced pancreatic cancer.

The researchers recruited patients with measurable locally advanced or metastatic pancreatic cancer. All subjects had never received chemotherapy for their advanced disease and had immunohistochemical evidence of EGFR expression.

Patients were treated with cetuximab at an initial dose of 400 mg/m2. This was followed by 250 mg/m2 weekly for 7 weeks.

Cetuximab with Gemcitabine for EGFR-expressing pancreatic cancer:
5 patients – partial response
26 patients – stable disease
Journal of Clinical Oncology

Gemcitabine was administered at 1000 mg/m2 for 7 weeks, followed by 1 week of rest.

In subsequent cycles, cetuximab was administered weekly, and gemcitabine was administered weekly for 3 weeks every 4 weeks.

A total of 61 patients were screened for EGFR expression, with 58 patients (95%) having at least 1 plus staining and being recruited onto the trial.

Five patients (12%) achieved a partial response, and 26 (63%) had stable disease.

The median time to disease progression was 3.8 months, with median overall survival duration of 7.1 months.

The researchers found that one-year progression-free survival and overall survival rates were 12% and 31.7%, respectively.

The most frequently reported grade 3 or 4 adverse events were neutropenia, which occurred in 39% of cases, asthenia (22%), abdominal pain (22%) and thrombocytopenia (17.%).

The authors conclude, "Cetuximab in combination with gemcitabine showed promising activity against advanced pancreatic cancer."

They add, however, that, "Further clinical investigation is warranted."

J Clin Oncol 2004; 22(13): 2610 – 2616
01 July 2004

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us